The Journal of Immunology, Vol 144, Issue 11 4189-4194, Copyright © 1990 by American Association of Immunologists

ARTICLES

Transforming growth factor-beta and cellular immune responses in synovial fluids

M Lotz, J Kekow and DA Carson
Department of Molecular and Experimental Medicine, Research Institute of Scripps Clinic, La Jolla, CA 92037.

Mononuclear cells in synovial fluids (SF) from patients with rheumatoid arthritis and other arthropathies are characterized by functional and phenotypic changes, including impaired mitogen responsiveness and inverted ratios of CD4+/CD8+ T lymphocytes. This is related to previously described activities in synovial fluids that inhibit proliferation of lymphocytes induced by mitogens and cytokines. The present study examines the relationship of these activities and transforming growth factor beta (TGF-beta), which is now known as the most potent endogenous inhibitor of lymphocyte function. It is shown that most of the activity in SF that inhibits IL-1-induced thymocyte or T cell proliferation is neutralized by a specific antibody to TGF-beta. Analysis of the SF in the CCL64 assay, a standard test for TGF-beta, showed a close correlation between the levels of immunosuppressive activity and TGF-beta. SF contain spontaneously active inhibitors of T cell function and this is caused by the presence of active TGF-beta. Higher titers are found after transient acidification, which is known to activate the latent form of TGF-beta. Characterization of the TGF- beta isoforms showed that most of the material in SF is TGF-beta 2. Analysis of TGF-beta effects on T cell subsets demonstrated that it completely inhibits proliferation of CD4+ cells whereas at the same concentrations of purified or rTGF-beta CD8+ cells are only inhibited by maximally 31.1%. SF also preferentially inhibit CD4+ Th cell proliferation and this effect is neutralized by antibody to TGF-beta. Collectively these results indicate that the presence of TGF-beta accounts for most of the immunosuppressive activities in SF and that this factor may be responsible for functional and phenotypic changes of SF lymphocytes.

This article has been cited by other articles:

				M. Sakuma, K. Hatsushika, K. Koyama, R. Katoh, T. Ando, Y. Watanabe, M. Wako, M. Kanzaki, S. Takano, H. Sugiyama, et al. TGF-{beta} type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody Int. Immunol., February 1, 2007; 19(2): 117 - 126. [Abstract] [Full Text] [PDF]

				R J Francois, L Neure, J Sieper, and J Braun Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor {alpha} in two patients with early disease and transforming growth factor {beta} in three more advanced cases Ann Rheum Dis, June 1, 2006; 65(6): 713 - 720. [Abstract] [Full Text] [PDF]

				A Scharstuhl, H M van Beuningen, E L Vitters, P M van der Kraan, and W B van den Berg Loss of transforming growth factor counteraction on interleukin 1 mediated effects in cartilage of old mice Ann Rheum Dis, December 1, 2002; 61(12): 1095 - 1098. [Abstract] [Full Text] [PDF]

				A. Scharstuhl, H. L. Glansbeek, H. M. van Beuningen, E. L. Vitters, P. M. van der Kraan, and W. B. van den Berg Inhibition of Endogenous TGF-{beta} During Experimental Osteoarthritis Prevents Osteophyte Formation and Impairs Cartilage Repair J. Immunol., July 1, 2002; 169(1): 507 - 514. [Abstract] [Full Text] [PDF]

				Y. Yamanishi, D. L. Boyle, M. Clark, R. A. Maki, M. D. Tortorella, E. C. Arner, and G. S. Firestein Expression and Regulation of Aggrecanase in Arthritis: The Role of TGF-{beta} J. Immunol., February 1, 2002; 168(3): 1405 - 1412. [Abstract] [Full Text] [PDF]

				C. D. Buckley, N. Amft, P. F. Bradfield, D. Pilling, E. Ross, F. Arenzana-Seisdedos, A. Amara, S. J. Curnow, J. M. Lord, D. Scheel-Toellner, et al. Persistent Induction of the Chemokine Receptor CXCR4 by TGF-{beta}1 on Synovial T Cells Contributes to Their Accumulation Within the Rheumatoid Synovium J. Immunol., September 15, 2000; 165(6): 3423 - 3429. [Abstract] [Full Text] [PDF]

				J. A G van Roon, C. M Verhoef, J. L A M van Roy, F. H J Gmelig-Meyling, O. Huber-Bruning, F. P J G Lafeber, and J. W J Bijlsma Decrease in peripheral type 1 over type 2 T cell cytokine production in patients with rheumatoid arthritis correlates with an increase in severity of disease Ann Rheum Dis, November 1, 1997; 56(11): 656 - 660. [Abstract] [Full Text]

				E. Raz, J. Dudler, M. Lotz, S.M. Baird, C.C. Berry, R.A. Eisenberg, and D.A. Carson Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery Lupus, August 1, 1995; 4(4): 286 - 292. [Abstract] [PDF]

				G. Del Giudice and M. K. Crow Review: Role of Transforming Growth Factor Beta (TGF{beta}) in Systemic Autoimmunity Lupus, August 1, 1993; 2(4): 213 - 220. [Abstract] [PDF]